Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 29 May, 2014 and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

AACE: Dapagliflozin Reduces Postprandial Glucose in Type 2 Diabetes

Dapagliflozin as an add-on therapy to glimepiride, pioglitazone, or sitagliptin significantly reduces postprandial plasma glucose in type 2 diabetes patients.... 

Advertisement

The US Food and Drug Administration approved dapagliflozin on January 8, 2014, for use in glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, lowers plasma glucose concentration by increasing renal glucose excretion, independent from insulin secretion.

The authors point out that control of fasting hyperglycemia alone may not be optimal for achieving long term glucose control, as indicated by HbA1c <7.0%, in patients with type 2 diabetes mellitus (T2DM). The current study evaluated postprandial glucose.

In three phase 3 randomized trials, type 2 diabetes patients received 10 mg/day dapagliflozin or placebo as an add-on therapy to glimepiride (n=596), pioglitazone (n=420) and sitagliptin with or without metformin (n=451).

The study showed that the addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo: placebo-corrected mean changes from baseline at 24 weeks in 2-hour postprandial plasma glucose for dapagliflozin were -49.1 (-64.1, -34.1) mg/dL with glimepiride, -53.3 (-71.1, -35.6) mg/dL with pioglitazone, and -42.9 (-52.1, -33.8) mg/dL with sitagliptin.

According to the authors, "Observational studies suggest that postprandial glucose may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.

"Higher postprandial blood glucose concentrations may lead to increased glucose filtration, allowing for greater glucose excretion with SGLT2 inhibition and effective postprandial glucose lowering, thus potentially preventing vascular complications," the authors write.

Practice Pearls:
  • The addition of dapagliflozin significantly reduced postprandial plasma glucose compared with placebo
  • PPG may be more predictive of cardiovascular morbidity and mortality and microvascular complications than fasting plasma glucose.
  • The number of adverse events was similar for dapagliflozin and placebo.

The study was presented at the American Association of Clinical Endocrinologists annual meeting held from May 14th to 18th in Las Vegas, Nevada. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  BG ControlType 2 DiabetesSGLT2Issue 731

Past five issues: Diabetes Clinical Mastery Series Issue 204 | Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0



Search Articles On Diabetes In Control